Femtopath citation update-4



Human Genomics (2016) 10:40; (SCI Impact factor=3.385)


The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.


Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutantenriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report another 2 novel Kras mutations (A11V, V14I).


Kuang-Leei Chang, Ming-Yung Lee, Wan-Ru Chao and Chih-Ping Han.

<Paper Weblink>

Click here